Royer Biomedical
Private Company
Funding information not available
Overview
Royer Biomedical is a private, US-based company founded in 1995, specializing in advanced polymer-based drug delivery systems. Its core technologies include synthetic hydrogel (AppliGel/VetriGel) and calcium-based (Matrix III) platforms designed for localized, sustained release of therapeutics to enhance efficacy and reduce systemic toxicity. The company has an active clinical program for a gentamicin-loaded gel for diabetic foot ulcers and is advancing veterinary applications, positioning itself at the intersection of novel drug delivery and targeted therapy.
Technology Platform
Proprietary synthetic polymer platforms for localized, sustained drug delivery. Includes: 1) AppliGel/VetriGel - sterile, injectable/topical hydrogel matrices that are biodegradable and non-immunogenic. 2) Matrix III - calcium-based, bio-erodible implantable matrices for depot delivery. Both designed for controlled elution and local site-specific action with minimal systemic exposure.
Opportunities
Risk Factors
Competitive Landscape
Royer competes in the advanced drug delivery sector against numerous public and private companies developing hydrogel, polymer, and implantable matrix technologies. Key differentiators claimed are its fully synthetic, non-immunogenic composition and dual-platform approach. Competitors range from large-cap medical device firms to specialty pharma companies with localized delivery products.